Orphine opioids in Europe are spreading fast, and the consequences are already fatal. Health authorities now link cychlorphine and spirochlorphine to dozens of deaths and a sharp rise in poisonings. The European Union Drugs Agency (EUDA) published formal initial reports on both substances in 2026, and the findings make for sobering reading.

What Are Orphine Opioids and Why Do They Matter?

Orphine opioids in Europe represent one of the fastest-growing drug threats the continent has seen. Cychlorphine and spirochlorphine belong to this emerging class. Both share structural similarities with brorphine and bezitramide, substances the United Nations already controls under Schedule I of the 1961 Single Convention on Narcotic Drugs.

Both drugs target the same brain receptors as heroin, fentanyl, and morphine. Animal and laboratory data suggest cychlorphine may exceed fentanyl in potency. Spirochlorphine appears to match fentanyl’s strength. Either way, the overdose risk is extreme. Respiratory depression is the main killer. A person’s breathing slows, then stops, often with no warning at all.

How Orphine Opioids in Europe Spread So Quickly

Sweden made the first confirmed seizure of cychlorphine in August 2024, recovering just under one gram of white-beige powder. The spread accelerated quickly. By March 2026, eleven EU member states and Norway each reported detecting the drug for the first time, including Austria, Estonia, Finland, France, Germany, Greece, Italy, Latvia, the Netherlands, Spain, and Sweden.

The seizure numbers tell the same story. Authorities across eight member states and Norway recorded 228 cychlorphine seizures between June 2024 and March 2026. The total volume jumped from 0.08 kg in 2024 to 5.78 kg in 2025. That is a more than 70-fold increase in a single year.

Spirochlorphine followed close behind. Sweden first seized it in January 2025. Eight member states later confirmed its presence. Latvia alone accounted for more than 99% of all spirochlorphine seized by weight.

The Death Toll Keeps Rising

The human cost of this synthetic opioid crisis in Europe is already devastating, and the figures keep climbing.

Four member states reported 31 confirmed deaths linked to cychlorphine between August 2024 and March 2026. Estonia led with 24 fatalities. Sweden recorded 5. Finland and the Netherlands each reported 1. Authorities assessed cychlorphine as the cause or a contributing factor in at least 17 of those 31 deaths. In 4 cases, it was the only substance present.

Non-fatal poisonings add to the picture. Two member states reported 11 confirmed acute poisonings involving cychlorphine between October 2025 and March 2026. Germany, Sweden, Spain, and the Netherlands reported a further seven suspected or probable cases.

Spirochlorphine has also claimed lives. Germany confirmed one death in January 2025. Czechia reported two life-threatening poisonings in the same person, in March and December 2025.

Who Uses These Drugs and How

Syringe residue studies in Estonia and Latvia show people who inject drugs now use orphine opioids in Europe at an alarming rate. In Latvia, cychlorphine turned up in 6% of used syringes in late 2024. By late 2025, that figure reached 56%. Spirochlorphine appeared in 7% of Latvian syringes in late 2024, and in 17% of syringes Estonia tested by mid-2025.

Injecting is not the only route. Authorities seized both drugs in blotters, vaping liquids, nasal sprays, and tablets. Germany uncovered a case where someone sold cychlorphine online disguised as a benzodiazepine pro-drug tablet. That product caused at least two deaths and several poisonings before sellers pulled it.

The variety of forms matters. It shows this synthetic opioid crisis in Europe now reaches people who do not inject drugs, including those who have no idea what they are consuming.

Replacing Nitazenes: A Deliberate Shift

China introduced generic controls on nitazene opioids in July 2025. That decision disrupted supply chains and reduced nitazene availability across European drug markets. Manufacturers and distributors responded by switching to alternatives. Cychlorphine and spirochlorphine filled the gap.

Since 2024, nine new orphine opioid substances have appeared on the European drug market. EUDA flagged this shift in a March 2026 advisory. The agency warned member states that the suppression of nitazene supply from China partly explains the surge in orphine availability.

Laboratories Miss These Drugs, Making the Crisis Harder to Track

Many European laboratories do not routinely screen for cychlorphine or spirochlorphine. That gap almost certainly means official death and poisoning counts fall short of the true numbers. Orphine opioids in Europe may cause far more harm than current statistics show.

Dealers sell both drugs openly under their own names, marketing them as legal alternatives to controlled opioids. That approach exploits the fact that 16 member states had not restricted cychlorphine at the time EUDA compiled its report, and 15 had not restricted spirochlorphine. Eleven member states had controls on cychlorphine in place, and twelve on spirochlorphine. The United Nations has assessed neither drug.

No Medical Use Exists for Either Substance

The European Medicines Agency searched its records and found no authorised, pending, or investigational medicinal product containing cychlorphine or spirochlorphine anywhere in Europe. No veterinary product uses them either. The only legitimate role either substance plays is as an analytical reference standard in forensic and clinical laboratories.

EUDA concluded that both drugs pose health and social risks at Union level. The agency recommends a formal risk assessment under EU drugs legislation. Both substances remain under intensive monitoring.

What to Do If Someone Is Exposed

Naloxone can reverse the respiratory depression these drugs cause, as it does with other opioids. EUDA flagged that drug-specific clinical data remain thin, so the exact doses and timing needed for effective treatment are still unclear.

If someone may have taken an unknown substance, call emergency services straight away. These drugs appear in forms that look nothing like traditional street drugs. The risk of accidental exposure is real, and every minute matters.

Source: dbrecoveryresources